Mehdi Gasmi, VP, Pharmaceutical Development at Avalanche Biotechnologies, Inc. ([AAVL]), sold 500 shares at $38.02 ($19K) on 2015-05-28, disclosed to the SEC on 2015-05-29.
Scheduled sale ($19k) by VP, Pharmaceutical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ADVM | SELL | 2020-06-18 | $563K | — | Filing → |
| ADVM | SELL | 2020-06-17 | $324K | — | Filing → |
| ADVM | SELL | 2020-05-22 | $100K | — | Filing → |